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Summary 
Several experimental methods exist to explore the microRNA (miRNA) regulome. These 
methods almost exclusively focus on multiple targets bound to a single, or perhaps a few 
miRNAs of interest. Here, we describe a microRNA capture affinity technology (miR-
CATCH) which uses an affinity capture oligonucleotide to co-purify a single target 
messenger RNA (mRNA) together with all its endogenously bound miRNAs. This bench-
top method is similar to RNA immunoprecipitation (RIP) and provides an experimental 
alternative to computational miRNA target prediction.  
Key words: MicroRNA, Affinity capture, MicroRNA target analysis, Oligonucleotide 
hybridisation, miR-CATCH  
3 
 
1. Introduction 
Various computational and experimental methods exist to explore the microRNA (miRNA) 
regulome. Among the latter, a number of exploratory experiments exist based on first 
principles to determine miRNA targets in vivo. Several RNA immunoprecipitation (RIP)-
based methods allow for the isolation of miRNA-target hybrids with the use of antibodies 
specific to the Ago proteins, the principal miRNA-carrying RNA binding proteins (RBPs) of 
the RNA-induced silencing complex (miRISC). Among these methods are tandem affinity 
purification of miRNA:mRNA (TAP-Tar) (1), high-throughput sequencing of RNA isolated 
by cross-linking immunoprecipitation (HITS-CLIP) (2) and photoactivatable-ribonucleoside-
enhanced cross-linking and immunoprecipitation (PAR-CLIP) (3).  
Besides immunopurification, a number of nucleic acid-based affinity capture methods exist. 
MiRNA target RNA affinity purification (miR-TRAP) reversibly cross-links a transfected 
biotinylated miRNA to its targets which are subsequently captured by streptavidin-coated 
beads (4). Aptamer-linked mRNA isolation, which involves the introduction of a vector 
containing an aptamer sequence and an RNA sequence of interest, can ‘fish’ for miRNAs 
and RBPs which bind to this RNA sequence (5). These can subsequently be co-purified with 
aptamer-binding proteins. 
Almost all of these methods take an approach that centres on an miRNA of interest, rather 
than using an mRNA target-focused approach. The exception is aptamer-linked mRNA, 
which still requires exogenous manipulation of live samples. 
To provide an in situ bench-top method to study all miRNAs endogenously bound to an 
mRNA target of interest and to overcome the limitations of current target-focused methods, 
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we developed an oligonucleotide affinity purification-based technique, we call miR-CATCH, 
to capture a target mRNA with all its attached miRNAs (6). Similar to RIP, miRISCs are 
reversibly cross-linked to their targets. Instead of immunopurification, biotinylated 
oligonucleotides complementary to predicted single-strand regions of the target mRNA 
capture that target with all its endogenously bound miRNAs through the use of 
streptavidin-coated magnetic beads. The reversal of the cross-links releases all individual 
components of the complex for further expression analysis. 
This method yields an RNA sample enriched with the miRNAs bound to a desired target 
mRNA and is of a quality and purity comparable to RIP-based methods. Subsequent 
analyses can be performed such as mRNA quantification, miRNA expression analysis and 
high-throughput profiling. 
 
  
5 
 
2. Materials 
RNase-free conditions are critical. All consumables should be RNase-free and filter pipette 
tips should be used. Prepare all salt solutions with analytical grade chemicals and treat with 
Diethylpyrocarbonate (DEPC) prior to the addition of Tris-EDTA (TE) buffer. RNase-free TE 
buffer should be prepared from a 100X stock solution. All buffers should be stored at 4°C 
and brought to room temperature prior to use. The protocol can be adapted to alternative 
equipment of similar purpose, although optimisation is recommended. 
2.1. Buffers 
1. FA Lysis Buffer: 140 mM NaCl, 50 mM HEPES (adjust to pH 7.5 with KOH), 1 mM 
EDTA, 1% v/v Triton-X 100, 0.1% w/v sodium deoxycholate. Always add PMSF, protease 
inhibitor cocktail and RNasin fresh before use. 
2. 2X B&W Buffer: 1X TE buffer (pH 7.5), 2 M NaCl. 
3. 1X B&W Buffer: 2X B&W Buffer, 50% v/v RNase-free water. 
4. Solution A: 0.1 M NaOH, 0.05 M NaCl. 
5. Solution B: 0.1 M NaCl. 
6. Hybridisation Buffer: 2X TE buffer (pH 7.5), 1 M LiCl. 
7. Wash Buffer A: 1X TE buffer (pH 7.5), 0.15 mM LiCl, 0.5% sodium dodecyl sulphate 
(SDS). 
8. Wash Buffer B: 1X TE buffer (pH 7.5), 0.15 mM LiCl. 
2.2. Reagents 
1. 0.5 mm RNase-free glass beads (SS Scientific, Eastbourne, UK) 
2. Dynabeads MyOne Streptavidin C1 (Life Technologies, Grand Island, USA) 
3. Paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA) 
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4. RiboSafe RNase Inhibitor (Promega, Madison, WI, USA) 
5. Complete Mini Protease Inhibitor Cocktail Tablets (Roche Applied Science, Penzberg, 
Germany) 
6. Phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich, St. Louis, MO, USA) 
7. Deoxyribonuclease I (DNase I) (Sigma-Aldrich, St. Louis, MO, USA) 
8. 100X Tris-EDTA buffer solution (Sigma-Aldrich, St. Louis, MO, USA) 
9. Biotin-triethylene glycol (TEG) 5’-modified single-stranded DNA oligonucleotides 
(Eurofins MWG Operon, Ebersberg, Germany) 
10. Dulbecco’s Phosphate-buffered saline (DPBS) (Lonza Group Ltd, Basel, Switzerland) 
2.3. Equipment 
1. DynaMag-2 (Life Technologies) 
2. FastPrep-24 (MP Biomedicals) 
3. Shake ‘n Stack hybridisation oven (Hybaid) 
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3. Method 
Perform the method at room temperature unless otherwise stated.  
3.1. Antisense Oligonucleotide design 
DNA oligonucleotide design is based on similar principles used for FISH probes, PCR 
primers and oligonucleotide affinity purification protocols. Besides single-stranded DNA 
oligonucleotides, locked nucleic acid (LNA) or morpholino probes could be used for 
improved specificity and hybridisation.  
Oligonucleotide hybridisation to any specific target mRNA is performed in high-salt 
conditions at 37°C. Under these conditions, the secondary structures of both the 
oligonucleotides and the target can significantly impede efficient hybridisation, as the self-
hybridised double-stranded regions of the two sequences will inhibit oligonucleotide 
binding. Oligonucleotide capture efficiency can be tested prior to the miR-CATCH protocol 
(see Note 1). 
An optimal capture oligonucleotide will have little ability to form harpins due to low self-
complementarity , a high hybrid melting temperature and will hybridise with a single-
stranded region of its target with high specificity (see Note 2 and 3). An oligonucleotide 
design strategy should use the following criteria: 
 The oligonucleotide must be modified at the 5’ terminal residue with biotin 
connected to a TEG spacer. 
 Oligonucleotides should be 18-25 residues in length. 
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 The oligonucleotide-target hybrid should have a melting temperature >50°C in 500 
mM monovalent salt conditions. 
 The target region shall be a single stranded at 37°C in 500 mM monovalent salt 
conditions as defined by RNA/DNA secondary structure prediction software. We 
used the mfold software (7). 
 The target region overlaps with no established or highly predicted binding regions 
for miRNAs or RBPs. 
 The oligonucleotide should have a melting temperature <37°C in 500 mM 
monovalent salt conditions as defined by RNA/DNA secondary structure prediction 
software. 
 The oligonucleotide should not contain stretches of more than three G or C residues. 
 The hybridisation energy of oligonucleotide dimers should be <15% of that of the 
hybrid. 
 Oligonucleotide complementarity with non-specific endogenous RNA sequences 
should be <15 bases. 
 For long RNA targets, multiple oligonucleotides to distant regions can improve 
yield. 
 
3.2. Sample preparation and cross-linking 
This protocol is designed for a cell pellet of approximately 100 mg or about 107 cells. 
Adjustment of the volumes used is recommended for a different cell quantity. Cross-linking 
conditions can be optimised (see Note 4) 
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1. From paraformaldehyde, prepare a fresh 10 ml stock of methanol-free 2% 
paraformaldehyde in DPBS at room temperature. 
2. Harvest and wash 107 cells in a 50 ml tube, resuspend in 10 ml normal growth 
medium at room temperature. 
3. Add 10 ml 2% formaldehyde to the cells and mix on a plate rocker for 10 minutes at 
average speed. 
4. Quench the formaldehyde cross-linking reaction by adding 1.33 ml 3 M glycine (~0.2 
M final concentration) and mix on the plate rocker for 5 minutes. 
5. Centrifuge at 2000 g for 5 minutes at 4°C. 
6. Discard all supernatant and resuspend in 50 ml ice cold PBS and centrifuge at 2000 g 
for 5 minutes at 4°C. 
7. Repeat step 6 once. 
8. Resuspend the pellet in 0.6 ml ice cold PBS. Transfer the cells suspension to a 1.5 ml 
screw-cap microtube and transfer any remaining cells in the 50 ml tube with another 
0.6 ml ice cold PBS. 
9. Centrifuge the cells at 2000 g for 5 minutes at 4°C and discard the supernatant. With 
a 20 μl pipette, remove the last drop of supernatant. 
10. Flash-freeze the cell pellet in liquid nitrogen. 
Stopping point: flash-frozen cell pellet can be stored at -80°C until use. 
 
3.3. Cell Lysis 
The lysing protocol has been designed for the FastPrep-24 cell homogeniser. Alternative 
lysing methods can be optimised for this protocol (see Note 5). 
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1. Prepare 1.4 ml FA lysis buffer with 1X protease inhibitor cocktail, 6 μl PMSF and 
120U RNasin. 
2. On ice, thaw the pellet in 0.4 ml prepared FA lysis buffer. 
3. Add 0.4 ml glass beads and homogenise the cells on the FastPrep 24 homogeniser 4 
times for 30 seconds at speed 5.5. Ensure the lysate remains on ice during the 5 
minute cool down periods. 
4. Separate the lysate from the glass beads by puncturing a hole in the bottom of the 
screw-cap microtube and centrifuging it into another microcentrifuge tube at 3500 g 
for 5 minutes at 4°C. 
5. Wash the beads by adding 0.4 ml FA lysis buffer and repeat the centrifugation as per 
step 3.3.4. 
6. Add 0.6 ml FA lysis buffer to the lysate, resuspend the pellet and add 120U RNasin. 
7. Optional: Perform DNase treatment by adding to the lysate 25 mM MgCl2, 5 mM 
CaCl2 and 120 μg DNase I. Incubate the lysate at 37°C for 15 minutes. 
8. Add 0.5 M EDTA to the lysate to a final concentration of 20 mM and briefly mix.  
9. Centrifuge at 18,000 g for 5 minutes at 4°C, transfer the supernatant to a new 
microtube and keep on ice until use (see Note 6).  
 
3.4. Magnetic bead preparation and oligonucleotide immobilisation 
Washing of MyOne Streptavidin C1 magnetic beads and immobilisation of the biotin-TEG 
modified oligonucleotide proceeds as per the manufacturer’s protocol with slight 
modifications. 
1. Resuspend the magnetic beads in the vial by vortexing for >30 seconds. 
11 
 
2. For one capture, transfer 200 μl magnetic beads to a 1.5 ml microtube and add 1 ml 
1X B&W Buffer at room temperature. 
For multiple captures, up to 400 μl magnetic beads can be added per 1.5 ml 
microtube. 
3. Place the microtube on the magnetic stand for 2 minutes and aspirate off the 
supernatant. 
4. Remove the microtube from the magnet and resuspend the beads in 1 ml 1X B&W 
Buffer. 
5. Repeat step 3-4 twice, for a total of 3 washes. 
6. Wash the beads twice in 1 ml Solution A for 2 minutes and capture with  a DynaMag-
2 (or similar apparatus) for 2 minutes after each wash. 
7. Wash the beads once in Solution B and magnetically capture for 2 minutes before 
aspirating off the supernatant. 
8. Resuspend the magnetic beads in 400 μl 2X B&W Buffer per 200 μl original volume 
of beads. 
9. To 400 μl beads, add 400 μl 2 μM oligonucleotides in 1X TE buffer and tumble the 
microtubes for 15 minutes to facilitate oligonucleotide immobilisation to the beads. 
10. Briefly wash the beads twice in 1 ml Hybridisation Buffer. 
11. Per capture, in a microtube, resuspend the beads in 0.7 ml Hybridisation buffer and 
0.5 ml 1X TE buffer, both prewarmed to 37°C. 
12. To this add 0.2 ml previously prepared lysate and agitate for 90 minutes at 37°C (see 
Note 7) 
13. While kept at 37°C, capture the beads with a magnet, discard the supernatant and 
resuspend in 1 ml Wash Buffer A prewarmed to 37°C. 
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14. Agitate the beads for 5 minutes at 37°C and capture the beads at 37°C for 2 minutes 
with a magnet. Discard the supernatant. 
15. Repeat steps 13-14 twice times with Wash Buffer A for a total of three washes, and 
perform twice with prewarmed Wash Buffer B. 
 
3.5. Elution and cross-link reversal 
1. To elute the target mRNA, vigorously resuspend the bead pellet in 30 μl 0.1X TE 
buffer (pH >7.5) preheated to 60°C.  
2. Incubate the bead mix at 60°C for 5 minutes and pellet the beads on the magnetic 
stand for 10-15 seconds. Transfer the supernatant to a new, labelled tube ensuring no 
beads are transferred. Also incubate a volume (>200 μl) of original lysate for use as a 
reference sample. 
3. To reverse the formaldehyde cross-links, incubate the eluent at 70°C for 45 minutes. 
Also incubate the volume of lysate from step 2 (see Note 8). 
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4. Notes 
1. To test the capture efficiency of the oligonucleotides, we strongly recommend 
performing a capture with samples which have not undergone formaldehyde cross-
linking. This can be performed by excluding steps 3.2.1, 3.2.3-3.2.4, 3.2.6-3.2.7. 
2. To establish the enrichment of the target gene of interest, qRT-PCR should be performed 
and should include at least one or multiple non-specific genes to measure the enrichment 
of the target gene over the background. The lysate can be used as a reference sample, 
which should undergo total RNA purification. 
3. To assess specificity of the oligonucleotide, we recommend performing a capture with 
non-targeting oligonucleotides with mismatch or scrambled sequences. To test 
selectivity, we recommend analysing the expression of non-targeted genes with the 
highest degree of complementarity besides the intended target. 
4. Careful preparation and timing of the cross-linking step is crucial as overtreatment will 
result in increased non-specific capture, while undertreatment will result in low miRNA 
co-purification. Depending on the sample, both formaldehyde concentration and 
incubation time can be optimised. 
5. Formaldehyde cross-linking makes cells more resistant to lysis. Mechanical disruption 
with the aid of FA lysis buffer is advised, but not limited to the method used in this 
protocol. Care must be taken to preserve RNA integrity. Sonication is not recommended 
as this frequently results in RNA fragmentation. 
6. Multiple simultaneous captures can be performed from the same lysate. Freezing and 
thawing lysate reduces capture efficiency. 
7. For efficient capture with minimal RNA degradation, the hybridisation incubation time 
(step 3.4.12) can be optimised (30 minutes – 4 hours). 
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8. The eluent should be pure enough for further downstream analyses. Further RNA 
purification could result in the loss of low expressed miRNAs. However the lysate 
should always undergo RNA purification for further analysis. 
  
15 
 
References. 
1.  N. Nonne, M. Ameyar-Zazoua, M. Souidi, et al. (2010) Tandem affinity purification of 
miRNA target mRNAs (TAP-Tar), Nucleic Acids Research. 38, e20–e20. 
2.  S.W. Chi, J.B. Zang, A. Mele, et al. (2009) Argonaute HITS-CLIP decodes microRNA-
mRNA interaction maps, Nature. 460, 479–486. 
3.  M. Hafner, M. Landthaler, L. Burger, et al. (2010) Transcriptome-wide identification of 
RNA-binding protein and microRNA target sites by PAR-CLIP, Cell. 141, 129–141. 
4.  H. Baigude, Ahsanullah, Z. Li, et al. (2012) miR-TRAP: A Benchtop Chemical Biology 
Strategy to Identify microRNA Targets, Angewandte Chemie. 124, 5982–5985. 
5.  S. Vasudevan, Y. Tong, and J.A. Steitz (2007) Switching from Repression to Activation: 
MicroRNAs Can Up-Regulate Translation, Science. 318, 1931–1934. 
6.  T. Hassan, S.G. Smith, K. Gaughan K, et al. (2013) Isolation and identification of cell-
specific microRNAs targeting a messenger RNA using a biotinylated anti-sense 
oligonucleotide capture affinity technique, Nucleic Acids Res. 41:e71.  
7. M. Zuker (2003) Mfold web server for nucleic acid folding and hybridization prediction, 
Nucleic Acids Research. 31, 3406–3415. 
 
  
16 
 
Figure  Captions 
Figure 1: 
The miR-CATCH workflow. (A) Oligonucleotide synthesis: a biotin-TEG-modified 
oligonucleotide is designed and synthesised for a predicted single-stranded region of the 
target RNA. (B) Formaldehyde cross-linking: miRISCs are cross-linked to their targets. (C) 
Oligonucleotide immobilisation: capture oligonucleotides are immobilised to magnetic 
streptavidin-coated beads. (D) Cell lysis: cells are lysed and precipitates removed. (E) Target 
capture and purification: the oligonucleotide-bead complexes capture the target of interest, 
while background is washed away. (F) Cross-link reversal: the formaldehyde cross-links are 
reversed by heat, releasing the target of interest and its associated miRNAs. 
Figure 2: 
Expected target enrichment. This graph represents typical target enrichments achieved from 
cross-linked cells (+ cross-linking) and from untreated cells (- cross-linking). Total RNA was 
used as a reference sample and several non-targeted genes were used to assess background. 
Higher background is expected in cross-linked samples compared to untreated samples, 
resulting in a lower, but still significant enrichment. 
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